Urinary Mannose-binding Lectin is a Biomarker for Predicting the Progression of Immunoglobulin (Ig)A Nephropathy

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2012 Jul 11

PMID 22774989

Citations 20

Authors

L-L Liu

Y Jiang

L-N Wang

N Liu

Affiliations

Soon will be listed here.

Abstract

Complement system activation is associated with immunoglobulin A nephropathy (IgAN) activity and progression. The aim of the present study was to investigate the importance of urinary mannose-binding lectin (MBL), at the time of renal biopsy, for evaluating disease severity and predicting the progression of IgAN. A total of 162 patients with biopsy-proven IgAN were enrolled and 50 healthy individuals were selected as normal controls. Urinary MBL was measured by sandwich enzyme-linked immunosorbent assay (ELISA) and normalized for urinary creatinine concentration. Urinary MBL was significantly higher in IgAN patients than that in normal controls, and elevated as histopathological phenotypes upgraded. Urinary MBL was correlated significantly with the well-known clinical predictors for the prognosis of IgAN; that is, renal function (represented by serum creatinine and estimated glomerular filtration rate), proteinuria and arterial hypertension. Urinary MBL was demonstrated to be correlated with the histopathological parameters which have independent value in predicting renal outcome of IgAN according to the Oxford classification; that is, mesangial hypercellularity, segmental glomerulosclerosis, endocapillary hypercellularity and tubular atrophy/interstitial fibrosis. More importantly, non-remission patients at the end of follow-up had significantly higher levels of urinary MBL compared with patients in remission. In conclusion, urinary MBL can be a reliable non-invasive biomarker for evaluating disease severity and predicting the prognosis of IgAN. This is the first report on this issue. However, our conclusions should be verified further in large-scale studies with long-term follow-up.

Citing Articles

Urine complement-related proteins in IgA nephropathy and IgA vasculitis nephritis, possible biomarkers of disease activity.

Nurmi M, Perez-Alos L, Garred P, Fellstrom B, Gabrysch K, Lundberg S Clin Kidney J. 2025; 18(1):sfae395.

PMID: 40008348 PMC: 11852328. DOI: 10.1093/ckj/sfae395.

Blood and urine biomarkers of disease progression in IgA nephropathy.

Duan Z, Zhang C, Chen X, Cai G Biomark Res. 2024; 12(1):72.

PMID: 39075557 PMC: 11287988. DOI: 10.1186/s40364-024-00619-4.

Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy.

Cattran D, Floege J, Coppo R Kidney Int Rep. 2023; 8(12):2515-2528.

PMID: 38106572 PMC: 10719597. DOI: 10.1016/j.ekir.2023.09.020.

IgA nephropathy.

Stamellou E, Seikrit C, Tang S, Boor P, Tesar V, Floege J Nat Rev Dis Primers. 2023; 9(1):67.

PMID: 38036542 DOI: 10.1038/s41572-023-00476-9.

IgA Nephropathy: A Chinese Perspective.

Zhang Z, Zhang Y, Zhang H Glomerular Dis. 2023; 2(1):30-41.

PMID: 36751266 PMC: 9677733. DOI: 10.1159/000520039.

References

Floege J, Feehally J . IgA nephropathy: recent developments. J Am Soc Nephrol. 2000; 11(12):2395-2403. DOI: 10.1681/ASN.V11122395. View

Tomino Y, Sakai H, Miura M, Endoh M, Nomoto Y . Detection of polymeric IgA in glomeruli from patients with IgA nephropathy. Clin Exp Immunol. 1982; 49(2):419-25. PMC: 1536483. View

Roos A, Rastaldi M, Calvaresi N, Oortwijn B, Schlagwein N, van Gijlswijk-Janssen D . Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006; 17(6):1724-34. DOI: 10.1681/ASN.2005090923. View

Matsuda M, Shikata K, Wada J, Sugimoto H, Shikata Y, Kawasaki T . Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron. 1998; 80(4):408-13. DOI: 10.1159/000045212. View

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

DAmico G, MINETTI L, Ponticelli C, Fellin G, Ferrario F, Barbiano di Belgioioso G . Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med. 1986; 59(228):363-78. View

Dohi K, Iwano M, Muraguchi A, Horii Y, Hirayama T, Ogawa S . The prognostic significance of urinary interleukin 6 in IgA nephropathy. Clin Nephrol. 1991; 35(1):1-5. View

Tan Y, Zhang J, Liu G, Zhang H, Zhao M . The level of urinary secretory immunoglobulin A (sIgA) of patients with IgA nephropathy is elevated and associated with pathological phenotypes. Clin Exp Immunol. 2009; 156(1):111-6. PMC: 2673748. DOI: 10.1111/j.1365-2249.2008.03868.x. View

Cattran D, Coppo R, Cook H, Feehally J, Roberts I, Troyanov S . The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76(5):534-45. DOI: 10.1038/ki.2009.243. View

10.

Miyazaki R, Kuroda M, Akiyama T, Otani I, Tofuku Y, Takeda R . Glomerular deposition and serum levels of complement control proteins in patients with IgA nephropathy. Clin Nephrol. 1984; 21(6):335-40. View

11.

Tomiyoshi Y, Sakemi T, Ikeda Y, Ohtsuka Y, Nakamura M, Fujisaki T . Cellular crescents and segmental glomerular necrosis in IgA nephropathy are indicative of the beneficial effects of corticosteroid therapy. Intern Med. 2001; 40(9):862-6. DOI: 10.2169/internalmedicine.40.862. View

12.

Katafuchi R, Oh Y, Hori K, Komota T, Yanase T, Ikeda K . An important role of glomerular segmental lesions on progression of IgA nephropathy: a multivariate analysis. Clin Nephrol. 1994; 41(4):191-8. View

13.

Wyatt R, Kanayama Y, Julian B, Negoro N, Sugimoto S, Hudson E . Complement activation in IgA nephropathy. Kidney Int. 1987; 31(4):1019-23. DOI: 10.1038/ki.1987.101. View

14.

Vassalotti J, Stevens L, Levey A . Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis. 2007; 50(2):169-80. DOI: 10.1053/j.ajkd.2007.06.013. View

15.

Coppo R, Amore A, Peruzzi L, Vergano L, Camilla R . Innate immunity and IgA nephropathy. J Nephrol. 2010; 23(6):626-32. View

16.

Wang L, Ni Z, Xie Z, Yang F, He B, Liu J . Analysis of the urine proteome of human contrast-induced kidney injury using two-dimensional fluorescence differential gel electrophoresis/matrix-assisted laser desorption time-of-flight mass spectrometry/liquid chromatography mass spectrometry. Am J Nephrol. 2009; 31(1):45-52. DOI: 10.1159/000255439. View

17.

Cote A, Brown M, Lam E, von Dadelszen P, Firoz T, Liston R . Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. BMJ. 2008; 336(7651):1003-6. PMC: 2364863. DOI: 10.1136/bmj.39532.543947.BE. View

18.

Torres D, Rossini M, Manno C, Mattace-Raso F, DAltri C, Ranieri E . The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int. 2007; 73(3):327-33. DOI: 10.1038/sj.ki.5002621. View

19.

Lee S, Rao V, Franklin W, Schiffer M, Aronson A, SPARGO B . IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982; 13(4):314-22. DOI: 10.1016/s0046-8177(82)80221-9. View

20.

Holmskov U, Malhotra R, Sim R, Jensenius J . Collectins: collagenous C-type lectins of the innate immune defense system. Immunol Today. 1994; 15(2):67-74. DOI: 10.1016/0167-5699(94)90136-8. View